Co-Author
This page shows the publications co-authored by Amir Fathi and Daniel DeAngelo.
Connection Strength
1.443
-
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
Score: 0.227
-
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018 09 13; 132(11):1125-1133.
Score: 0.207
-
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
Score: 0.197
-
Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88.
Score: 0.177
-
Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
Score: 0.055
-
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
Score: 0.054
-
Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
Score: 0.052
-
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
Score: 0.051
-
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 01 25; 131(4):387-396.
Score: 0.049
-
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017 09; 15(9):1091-1102.
Score: 0.049
-
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 08 10; 130(6):722-731.
Score: 0.048
-
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
Score: 0.045
-
Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
Score: 0.044
-
Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
Score: 0.041
-
Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw. 2014 Nov; 12(11):1590-610.
Score: 0.040
-
Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw. 2013 Nov; 11(11):1327-40.
Score: 0.037
-
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20.
Score: 0.036
-
Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2012 Jan; 10(1):64-110.
Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.